Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06787690

Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds

A Prospective Multicenter Single-arm Clinical Study to Investigate Clinical Outcomes When Cohealyx™ is Used for the Management of Full Thickness Wounds Post-surgical Excision

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
41 (actual)
Sponsor
Avita Medical · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The goal of this study is to look at clinical outcomes when Cohealyx Collagen Matrix is used to treat full thickness wounds after surgical excision in patients that require a skin graft to heal their wounds. The main question it aims to answer is how long does it take for Cohealyx to support definitive closure.

Detailed description

This is a prospective single-arm post-market multicenter study to evaluate clinical outcomes of Cohealyx when used to manage full thickness wounds post-surgical excision. A systematic literature review and meta-analysis were conducted to establish a performance goal for the primary effectiveness endpoint (time to autografting). Patients with a full thickness wound where autografting is clinically indicated will be considered for participation in this study. Patients will undergo a staged surgical procedure for wound closure. In the first surgery, Cohealyx will be applied to the surgically excised wound bed within 5-days post-injury. Following placement of Cohealyx, investigators will evaluate the wound every 3 days. Once Cohealyx has successfully integrated into the wound bed, as indicated by a robust vascularized tissue bed, the wound bed will be prepared and autografted per the investigative site's standard of care. The study area will be evaluated with respect to Cohealyx integration, time to autografting, autograft take, healing, and safety-related adverse events. Post-autografting, subjects will be followed for 6.5 months. Treatment-related and serious adverse events will be reported through the duration of the study. At all visits, subjects' study treatment areas as well as any donor sites dressed in PermeaDerm will be documented using digital photography.

Conditions

Interventions

TypeNameDescription
DEVICECohealyxCohealyx application, followed by autologous split-thickness skin graft

Timeline

Start date
2025-05-15
Primary completion
2026-02-10
Completion
2026-08-01
First posted
2025-01-22
Last updated
2026-03-12

Locations

18 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06787690. Inclusion in this directory is not an endorsement.